Alex Sapir, incoming Fulcrum Therapeutics CEO
Still under clinical hold, Fulcrum locks in seasoned commercial leader as CEO
Fulcrum Therapeutics has recruited a new chief executive well versed in the marketing world amid management upheaval, a full clinical hold for its sickle cell program and a Phase III for a different rare disease drug.
Alex Sapir, who served as CEO at ReViral until Pfizer bought it last April, will replace Robert Gould as Fulcrum CEO on July 1. But that’s not the only change happening at the top: In its quarterly report, Fulcrum also revealed that CFO Esther Rajavelu has resigned, although she will remain in a consulting role.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters